Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Recent Advances in Orthopaedic Oncology
share announcement

Recent Advances in Orthopaedic Oncology

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (31 August 2022) | Viewed by 6211

Special Issue Editor

Dr. Tomoki Nakamura

E-Mail Website
Guest Editor
Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu 514-8570, Japan
Interests: orthopedic oncology; soft tissue sarcoma; bone sarcoma; metastasis; limb salvage surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Bone and soft tissue sarcomas are infrequent and heterogenous tumours that account for 1% of all cancers. Distant metastasis is relatively common in high-grade tumours, and many basic studies focus on developing new systemic therapies for improving survival. Clinical research focuses on oncologic and functional outcomes after local and systemic treatment of tumours.

Orthopaedic oncology also includes benign tumours. Some benign tumours such as giant cell tumours, solitary bone tumours, and desmoid tumours are often problematic and should be discussed.  

We are pleased to invite you to submit your work to this Special Issue on “Recent Advances in Orthopaedic Oncology”. This Special issue aims to clinically investigate new diagnostic and therapeutic techniques. We also investigate the possible applications for future treatment in basic studies.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: bone sarcoma, soft tissue sarcoma, and benign bone and soft tissue tumours.

I look forward to receiving your contributions.

Dr. Tomoki Nakamura
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

9 pages, 1413 KiB  
Article
Is Lymphocyte C-Reactive Protein Ratio Useful for Predicting Survival in Patients with Non-Metastatic Soft Tissue Sarcoma?
by Tomoki Nakamura, Tomohito Hagi, Kunihiro Asanuma and Akihiro Sudo
Cancers 2022, 14(21), 5214; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14215214 - 24 Oct 2022
Cited by 4 | Viewed by 797
Abstract
Background: Recently, the lymphocyte-to-CRP ratio (LCR) was found to have a prognostic role in many cancers. However, the clinical significance of LCR in patients with soft tissue sarcoma (STS) has not yet been established. This study aimed to determine whether LCR can predict [...] Read more.
Background: Recently, the lymphocyte-to-CRP ratio (LCR) was found to have a prognostic role in many cancers. However, the clinical significance of LCR in patients with soft tissue sarcoma (STS) has not yet been established. This study aimed to determine whether LCR can predict disease-specific survival (DSS) and event-free survival (EFS) in patients with STS. Methods: In this study, 132 patients were enrolled. The mean follow-up periods were 76.5 months. Blood examinations were performed prior to treatment for all patients. Results: The 5-year DSS in patients with higher and lower LCR was 86.5% and 52.8%, respectively (p < 0.001). Patients with lower LCR had worse survival than those with higher LCR. The 5-year EFS in patients with higher and lower LCR was 66.2% and 31.2%, respectively (p < 0.001). On Receiver operating characteristic analysis, however, there was no significant difference in the area under curve (AUC) between CRP level (AUC = 0.72) and LCR (AUC = 0.711). Conclusions: LCR may be a prognostic factor for predicting oncological events in multivariate analysis, although ROC analysis could not show the superiority of LCR to CRP for predicting oncological outcomes in patients with STS. Full article
(This article belongs to the Special Issue Recent Advances in Orthopaedic Oncology)
►▼ Show Figures

Figure 1

10 pages, 422 KiB  
Article
Prognostic Factors of Pulmonary Metastasectomy for Soft Tissue Sarcomas Arising in the Trunk Wall and Extremities
by Shizuhide Nakayama, Eisuke Kobayashi, Jun Nishio, Yu Toda, Masaya Yotsukura, Shun-Ichi Watanabe, Takuaki Yamamoto and Akira Kawai
Cancers 2022, 14(14), 3329; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14143329 - 08 Jul 2022
Cited by 1 | Viewed by 1172
Abstract
Although there is no evidence from prospective randomized controlled trials to support this practice, pulmonary metastases of sarcomas are often treated surgically if they are resectable. The purpose of this retrospective study was to evaluate the prognostic factors and outcome of pulmonary metastasectomy [...] Read more.
Although there is no evidence from prospective randomized controlled trials to support this practice, pulmonary metastases of sarcomas are often treated surgically if they are resectable. The purpose of this retrospective study was to evaluate the prognostic factors and outcome of pulmonary metastasectomy (PM) for soft tissue sarcomas (STSs) arising in the trunk wall and extremities in 66 consecutive patients. Prognostic factors associated with disease-specific survival after PM were evaluated using univariate and multivariate analyses. The patients included 38 men and 28 women, with a median age of 49 years. The median disease-specific survival after PM was 48 months, and the 5-year survival rate was 45%. No major perioperative complications occurred. Disease-free interval (<12 months), size of largest lung lesion (≥20 mm), and non-curative resection were independent prognostic factors in multivariate analysis. PM was effective in selected patients with pulmonary metastases from STSs arising in the trunk wall and extremities. Disease-free interval, maximum size of metastases, and resectability were identified as prognostic factors. Full article
(This article belongs to the Special Issue Recent Advances in Orthopaedic Oncology)
►▼ Show Figures

Figure 1

11 pages, 591 KiB  
Article
Clinical Outcome of Patients with Pelvic and Retroperitoneal Bone and Soft Tissue Sarcoma: A Retrospective Multicenter Study in Japan
by Toshiyuki Takemori, Teruya Kawamoto, Hitomi Hara, Naomasa Fukase, Shuichi Fujiwara, Ikuo Fujita, Takuya Fujimoto, Masayuki Morishita, Kazumichi Kitayama, Shunsuke Yahiro, Tomohiro Miyamoto, Masanori Saito, Jun Sugaya, Katsuhiro Hayashi, Hiroyuki Kawashima, Tomoaki Torigoe, Tomoki Nakamura, Hiroya Kondo, Toru Wakamatsu, Munenori Watanuki, Munehisa Kito, Satoshi Tsukushi, Akihito Nagano, Hidetatsu Outani, Shunichi Toki, Shunji Nishimura, Hiroshi Kobayashi, Itsuo Watanabe, Yusuke Demizu, Ryohei Sasaki, Takumi Fukumoto, Takahiro Niikura, Ryosuke Kuroda and Toshihiro Akisueadd Show full author list remove Hide full author list
Cancers 2022, 14(12), 3023; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14123023 - 20 Jun 2022
Cited by 1 | Viewed by 1714
Abstract
This study aimed to retrospectively analyze the clinical outcomes of patients with pelvic and retroperitoneal bone and soft tissue sarcoma (BSTS). Overall, 187 patients with BSTS in the pelvis and retroperitoneal region treated at 19 specialized sarcoma centers in Japan were included. The [...] Read more.
This study aimed to retrospectively analyze the clinical outcomes of patients with pelvic and retroperitoneal bone and soft tissue sarcoma (BSTS). Overall, 187 patients with BSTS in the pelvis and retroperitoneal region treated at 19 specialized sarcoma centers in Japan were included. The prognostic factors related to overall survival (OS), local control (LC), and progression-free survival (PFS) were evaluated. The 3-year OS and LC rates in the 187 patients were 71.7% and 79.1%, respectively. The 3-year PFS in 166 patients without any distant metastases at the time of primary tumor diagnosis was 48.6%. Osteosarcoma showed significantly worse OS and PFS than other sarcomas of the pelvis and retroperitoneum. In the univariate analyses, larger primary tumor size, soft tissue tumor, distant metastasis at the time of primary tumor diagnosis, P2 location, chemotherapy, and osteosarcoma were poor prognostic factors correlated with OS. Larger primary tumor size, higher age, soft tissue tumor, chemotherapy, and osteosarcoma were poor prognostic factors correlated with PFS in patients without any metastasis at the initial presentation. Larger primary tumor size was the only poor prognostic factor correlation with LC. This study has clarified the epidemiology and prognosis of patients with pelvic and retroperitoneal BSTS in Japan. Full article
(This article belongs to the Special Issue Recent Advances in Orthopaedic Oncology)
►▼ Show Figures

Figure 1

11 pages, 1134 KiB  
Article
Long-Term Results of Kyocera Modular Limb Salvage System after Resection of Tumors in the Distal Part of the Femur: Report from Japanese Musculoskeletal Oncology Group Study
by Tomoki Nakamura, Akihiko Matsumine, Yu Toda, Satoshi Takenaka, Hidetatsu Outani, Tomohiro Fujiwara, Yoshihiro Nishida, Satoshi Tsukushi, Yasunori Tome, Teruya Kawamoto, Munehisa Kito, Naohiro Shinohara, Masato Tomita, Tomoaki Torigoe, Akihiro Sudo and Hirotaka Kawano
Cancers 2022, 14(4), 870; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14040870 - 10 Feb 2022
Cited by 2 | Viewed by 1831
Abstract
Background: The distal femur is a common site of bone tumors. After surgical resection, prosthetic replacement is a major reconstruction method. We aimed to elucidate the long-term outcomes of the Kyocera Modular Limb Salvage (KMLS) systems after resection of tumors in the distal [...] Read more.
Background: The distal femur is a common site of bone tumors. After surgical resection, prosthetic replacement is a major reconstruction method. We aimed to elucidate the long-term outcomes of the Kyocera Modular Limb Salvage (KMLS) systems after resection of tumors in the distal part of the femur. Methods: Between 1998 and 2014, 125 patients were treated at 14 institutions. There were 59 males and 66 females, with a mean age of 35 years. The mean follow-up period was 132 months. Results: There had been 65 additional surgeries, including 56 revisions and 9 amputations: 15 for aseptic loosening, 14 for stem breakage, 13 for deep infection, 13 for rotator-hinge bushing failure, 5 for local recurrence, and 5 for others. Implant survival rates at 10 and 15 years were 58.5% and 39.4%. The cumulative incidence of 15-year revision for femoral stem breakage was 31.7% in patients with cementless fixation. The 15-year cumulative incidence of revision for aseptic loosening was 19.8% in patients with cement fixation. Conclusions: KMLS systems represent a reliable system with long-term results. Stem breakage should be considered in patients with cementless and/or smaller femoral stem sizes. Aseptic loosening should be considered in patients with cement systems after 10 years. Full article
(This article belongs to the Special Issue Recent Advances in Orthopaedic Oncology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop